Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
Helen R. Stagg
, Peter A. White, Vija Riekstiņa, Andra Cīrule, Ģirts Šķenders, Vaira Leimane1
, Liga Kuksa1
, Gunta Dravniece, James Brown, and Charlotte Jackson
Author affiliations: University College London, London, UK (H.R. Stagg, J. Brown, C. Jackson); Medical Research Council Centre for Outbreak Analysis and Modelling, London (P.J. White); National Institute for Health Research Health Protection Research Unit in Modelling Methodology, London (P.J. White); Imperial College School of Public Health, London (P.J. White); Public Health England, London (P.J. White); University of Latvia, Riga, Latvia (V. Riekstiņa); Riga East University Hospital, Riga (V. Riekstiņa, A. Cīrule, Ģ. Šķenders, V. Leimane, L. Kuksa); KNCV Tuberculosis Foundation, The Hague, the Netherlands (G. Dravniece); Royal Free London National Health Service Trust, London (J. Brown)
Figure 3. Relationship between use of Xpert MTB/RIF (Xpert) and time to treatment initiation among patients with multidrug-resistant tuberculosis (MDR TB) Latvia, 2009–2012. Shown are percentages of MDR-TB patients that underwent Xpert MTB/RIF testing (bars) and median time to treatment initiation (lines) with binomial distribution–derived CIs (error bars) for A) all patients and B) patients with and without testing by Xpert. MTB, Mycobacterium tuberculosis; RIF, rifampin.
Page created: March 01, 2016
Page updated: March 01, 2016
Page reviewed: March 01, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.